News Sentiment

ASRT sentiment intelligence

Assertio Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 23.50 Week of 19 Jun 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

75/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+0.1% over one week, +0.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Press Release: Assertio Provides Update on Garda Therapeutics Tender Process

Market Reaction

Balanced read

47/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 75/100 classification
One-week reaction 0.1% Price digesting
Trend fit Trend active 0.3% over four weeks
Fair value 25.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 29
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 18
Market source 9
Quartr 6
TradingKey 3
TMX Newsfile 2
Investing.com 2
Moomoo 1
Machine Maker 1

Event Lens

What the news is about

Classified themes
Market update 20
Deals and strategy 17
Earnings 5
Regulatory and legal 3
Guidance 2
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Moomoo Direct company coverage

Press Release: Assertio Provides Update on Garda Therapeutics Tender Process

Assertio Holdings, Inc. announced an update regarding the tender offer for all outstanding shares of Garda Therapeutics Inc. The tender offer period, which began on March 29, 2023, has been extended several times and is now set to expire on July 24, 2026. As of July 10, 2026, app

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 07:11
Source
Moomoo
Quartr Direct company coverage

Assertio (ASRT) Small-Cap Growth Virtual Investor Conference Summary

This summary details Assertio Holdings Inc.'s financial performance and strategic outlook discussed at the Small-Cap Growth Virtual Investor Conference on February 1, 2026. The company reported strong Q1 financials, reaffirmed its 2024 guidance, and highlighted Rolvedon as its pr

Tone
Positive 66/100
Event
Guidance
Published
11 Jul 2026 00:39
Source
Quartr
Quartr Direct company coverage

Assertio (ASRT) Proxy Filing Summary

Assertio (ASRT) has released a summary of its Proxy Filing for an Annual Meeting scheduled for May 7, 2025. Key topics for the meeting include the election of seven directors, approval of an amendment to the 2014 Omnibus Incentive Plan, an advisory vote on executive compensation,

Tone
Neutral 50/100
Event
Regulatory and legal
Published
10 Jul 2026 17:10
Source
Quartr
Quartr Direct company coverage

Assertio (ASRT) Q4 2025 earnings summary

Assertio (ASRT) reported its Q4 and full-year 2025 earnings, exceeding guidance for net product sales and adjusted EBITDA under new leadership. The company is refocusing on ROLVEDON as its core growth asset, completing its integration and optimizing commercial infrastructure for

Tone
Positive 66/100
Event
Earnings
Published
09 Jul 2026 00:39
Source
Quartr
Quartr Direct company coverage

Assertio (ASRT) Maxim Group’s 2024 Healthcare Virtual Summit Summary

This article summarizes Assertio's (ASRT) presentation at Maxim Group’s 2024 Healthcare Virtual Summit, highlighting the company's strategic shift from a broad portfolio to a focus on 7 key assets, with Rolvedon as the primary growth driver. Assertio aims to expand Rolvedon's mar

Tone
Positive 66/100
Event
Market update
Published
09 Jul 2026 00:39
Source
Quartr
Quartr Direct company coverage

Assertio (ASRT) Q1 2026 earnings summary

Assertio (ASRT) reported its Q1 2026 earnings, detailing the sale of non-ROLVEDON assets for $35M and a merger agreement with Garda Therapeutics. The company experienced a significant revenue decline to $9.9M, leading to a net loss of $18.9M, primarily due to lower ROLVEDON and I

Tone
Negative 27/100
Event
Deals and strategy
Published
09 Jul 2026 00:39
Source
Quartr
Quartr Direct company coverage

Assertio (ASRT) Q4 2024 earnings summary

Assertio (ASRT) reported its Q4 and full-year 2024 earnings, highlighting a stabilization year with Rolvedon sales exceeding $60 million and optimized portfolio management resulting in over $26 million in operating cash flow. The company strengthened its balance sheet and made le

Tone
Positive 63/100
Event
Earnings
Published
08 Jul 2026 12:10
Source
Quartr
Stock Titan Direct company coverage

Assertio Holdings (NASDAQ: ASRT) common stock struck from Nasdaq list

Assertio Holdings, Inc. (ASRT) common stock has been removed from listing and registration on the Nasdaq Stock Market LLC, as indicated by a Form 25 SEC filing. This voluntary withdrawal means the exchange and issuer complied with rules governing such removal due to Section 12(b)

Tone
Negative 32/100
Event
Market update
Published
07 Jul 2026 14:39
Source
Stock Titan
TMX Newsfile Direct company coverage

Assertio Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against Assertio Holdings, Inc. (NASDAQ: ASRT) and reminds investors of a March 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Assertio made false or

Tone
Negative 8/100
Event
Regulatory and legal
Published
07 Jul 2026 11:40
Source
TMX Newsfile
TMX Newsfile Direct company coverage

ASRT CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds Assertio Holdings, Inc. (ASRT) Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

Kessler Topaz Meltzer & Check, LLP has filed a securities class action lawsuit against Assertio Holdings, Inc. (NASDAQ: ASRT), citing violations of federal securities laws due to alleged omissions and fraudulent misrepresentations. The lawsuit stems from significant stock price d

Tone
Negative 8/100
Event
Regulatory and legal
Published
05 Jul 2026 11:10
Source
TMX Newsfile
Machine Maker Direct company coverage

Zydus Lifesciences Completes Acquisition of Assertio Holdings

Zydus Lifesciences has successfully completed its tender offer for the acquisition of Assertio Holdings Inc., marking a strategic expansion into the US pharmaceutical market. Assertio shareholders received $23.50 per share in cash, and Assertio will become a wholly-owned subsidia

Tone
Positive 73/100
Event
Deals and strategy
Published
29 Jun 2026 20:40
Source
Machine Maker
Stock Titan Direct company coverage

[15-12G] Assertio Holdings, Inc. SEC Filing

Assertio Holdings, Inc. has filed Form 15-12G with the SEC, certifying the termination of its registration under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of its duty to file reports under Sections 13 and 15(d). The filing, dated June 26, 2026, was s

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

[EFFECT] Assertio Holdings, Inc. SEC Filing

This article reports on an SEC filing (Form EFFECT) by Assertio Holdings, Inc. (ASRT), which received a neutral impact and sentiment rating. The filing indicates an effectiveness date of June 17, 2026, for a Notice of Effectiveness related to access number 0001104659-26-074620. A

Tone
Neutral 50/100
Event
Analyst action
Published
22 Jun 2026 20:10
Source
Stock Titan
Indian Pharma Post Direct company coverage

Zydus’s acquisition of Assertio to bolster its specialty pharma presence in US market

Zydus Lifesciences Ltd. has completed its cash tender offer to acquire U.S.-based Assertio Holdings, Inc. for $23.50 per share. Upon finalization, Assertio will become a wholly-owned subsidiary of Zydus and will be delisted from Nasdaq. This acquisition aims to strengthen Zydus'

Tone
Positive 71/100
Event
Deals and strategy
Published
20 Jun 2026 05:09
Source
Indian Pharma Post
TradingKey Direct company coverage

Assertio Holdings Inc (ASRT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article details the revenue breakdown for Assertio Holdings Inc (ASRT), providing insights into its performance by business segment and geographical region. The company's revenue streams are primarily driven by products like ROLVEDON, INDOCIN, and Sympazan, with the United S

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 13:10
Source
TradingKey
TradingKey Direct company coverage

Assertio Holdings Inc (ASRT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Assertio Holdings Inc (ASRT), listing major institutional shareholders like Nantahala Capital Management and Opaleye Management, along with their respective holdings. It also breaks down shareholder types, institutional shareholdi

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 13:10
Source
TradingKey
TradingKey Direct company coverage

Assertio Holdings Inc (ASRT) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Assertio Holdings Inc (ASRT), noting its current earnings forecast score, average price target of $3.00, and analyst ratings. It also includes a peer comparison and answers FAQs regarding revenue expectations, price targets, recent EP

Tone
Positive 61/100
Event
Earnings
Published
18 Jun 2026 10:10
Source
TradingKey
Medical Dialogues Direct company coverage

Zydus Completes USD 166.4 Million Acquisition of US-Based Assertio Holdings

Zydus Lifesciences has completed its acquisition of US-based Assertio Holdings Inc. for $166.4 million. Through its wholly-owned subsidiary, Zara Merger Sub Inc, Zydus successfully concluded the cash tender offer for all outstanding shares of Assertio. As a result, Assertio is no

Tone
Positive 72/100
Event
Deals and strategy
Published
17 Jun 2026 16:06
Source
Medical Dialogues
Stock Titan Direct company coverage

Assertio (ASRT) director fully cashes out shares and options in Zydus $23.50-per-share merger

Assertio Holdings, Inc. director William McKee has fully disposed of his equity, including 27,936 shares of common stock and two stock option grants, as part of the company's cash sale to Zydus. A Zydus subsidiary acquired all outstanding Assertio shares at $23.50 per share, lead

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 15:39
Source
Stock Titan
Stock Titan Direct company coverage

Assertio (ASRT) director cashes out shares and options in Zydus merger

Assertio Holdings director Heather L. Mason has disposed of all her equity in Assertio following its merger with Zydus entities. Her common shares and eligible stock options were cashed out at $23.50 per share through a tender offer that became effective on June 16, 2026. The For

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 04:40
Source
Stock Titan
Stock Titan Direct company coverage

Zydus buys Assertio (ASRT); EVP Schlessinger equity cashed out at $23.50

Assertio Holdings, Inc.'s EVP and General Counsel, Sam Schlessinger, cashed out all his equity, including common shares, stock options, and restricted stock units, as part of the company's merger with Zydus Worldwide DMCC. Zydus successfully completed a tender offer for Assertio'

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 04:10
Source
Stock Titan
Stock Titan Direct company coverage

Assertio (ASRT) COO exits stock, options and RSUs in $23.50-per-share cash merger

Assertio Holdings, Inc.'s President and COO, Paul Schwichtenberg, reported the disposition of his equity awards following the company's merger with Zydus entities. The merger, which made Assertio a wholly-owned subsidiary, involved a tender offer where all common shares were acqu

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 02:35
Source
Stock Titan
Stock Titan Direct company coverage

CFO Ajay Patel exits Assertio (ASRT) stake in $23.50-per-share merger

Assertio Holdings, Inc. CFO Ajay Patel has exited all his equity holdings in the company, including 15,942 common shares and various stock options and restricted stock units, as part of Assertio's cash merger with Zydus entities. The merger involved a tender offer of $23.50 per s

Tone
Positive 71/100
Event
Deals and strategy
Published
16 Jun 2026 22:39
Source
Stock Titan
Stock Titan Direct company coverage

Assertio (ASRT) director’s shares and options cashed out in $23.50 Zydus buyout

Assertio Holdings, Inc. director Sravan Kumar Emany reported that all his equity in the company, including 23,855 shares and various stock options, was cashed out as part of Assertio's merger with Zydus Worldwide DMCC. The common shares were disposed of at the tender offer price

Tone
Neutral 50/100
Event
Deals and strategy
Published
16 Jun 2026 22:39
Source
Stock Titan
Stock Titan Direct company coverage

Assertio (ASRT) CEO exits all shares and awards in $23.50-per-share cash merger

Assertio Holdings, Inc. CEO Mark L. Reisenauer disposed of all his equity interests in connection with Assertio’s cash merger with an affiliate of Zydus. A tender offer acquired all outstanding Assertio common shares at $23.50 per share in cash, resulting in the cancellation and

Tone
Neutral 50/100
Event
Deals and strategy
Published
16 Jun 2026 22:39
Source
Stock Titan
Stock Titan Direct company coverage

Assertio Holdings (ASRT) director exits as Zydus cash merger pays $23.50

Assertio Holdings director Kirk Sigurd has disposed of all his equity in the company following its merger with Zydus. His 12,017 common shares were converted to cash at $23.50 per share, and all stock options were either cashed out or cancelled according to the merger terms. This

Tone
Neutral 50/100
Event
Deals and strategy
Published
16 Jun 2026 22:39
Source
Stock Titan